Loading...
Loading...
Proteo
PTEO and its wholly-owned subsidiary Proteo Biotech
AG today announced that the NHS Lothian's Edinburgh Heart Centre has
successfully completed patient recruitment and treatment for the Phase
II clinical trial (EMPIRE study) with Proteo's drug candidate Elafin for
prevention of myocardial injury after coronary artery bypass surgery
(CABG). According to plan top-line results from this trial are expected
to be announced in the first quarter of 2014.
The EMPIRE (Elafin Myocardial Protection from Ischaemia Reperfusion
Injury) study is a placebo-controlled, double-blinded, Phase 2 clinical
trial to investigate the efficacy and safety of Elafin in coronary
bypass surgery which was started in the third quarter of 2011. The
preoperative Elafin treatment
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in